½ÃÀ庸°í¼­
»óǰÄÚµå
1802014

Æ®·Òºó ½ÃÀå ±Ô¸ð, Á¡À¯À², ¼ºÀå ºÐ¼® : Á¦Ç°º°, Á¦Çüº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº° - »ê¾÷ ¿¹Ãø(2025-2032³â)

Thrombin Market Size, Share, and Growth Analysis, By Product (Bovine Thrombin, Human Thrombin), By Dosage Form (Powder Form, Solution Form), By End-User, By Region - Industry Forecast 2025-2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: SkyQuest | ÆäÀÌÁö Á¤º¸: ¿µ¹® 173 Pages | ¹è¼Û¾È³» : 3-5ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ Æ®·Òºó ½ÃÀå ±Ô¸ð´Â 2023³â¿¡ 6¾ï 2,840¸¸ ´Þ·¯·Î Æò°¡µÇ¸ç, 2024³â 6¾ï 6,296¸¸ ´Þ·¯¿¡¼­ 2032³â¿¡´Â 10¾ï 1,744¸¸ ´Þ·¯·Î ¼ºÀåÇϸç, ¿¹Ãø ±â°£(2025-2032³â)ÀÇ CAGRÀº 5.5%·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù.

Æ®·Òºó ½ÃÀåÀº ƯÈ÷ ¼ö¼úÀ̳ª ¿Ü»ó »óȲ¿¡¼­ ÁöÇ÷°ú Ç÷¾× ÀÀ°í¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ÇÔÀ¸·Î½á °ý¸ñÇÒ ¸¸ÇÑ ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù. ½ÉÇ÷°ü¿Ü°ú, Á¤Çü¿Ü°ú µî ¿Ü°ú¼ö¼ú Áõ°¡¿Í °í·ÉÈ­ Àα¸ Áõ°¡·Î ÀÎÇØ ´õ ³ªÀº ÀÇ·á ¼­ºñ½º¸¦ ¿øÇÏ´Â Àα¸ Áõ°¡°¡ ÁÖ¿ä ¼ºÀå ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ÀçÁ¶ÇÕ Æ®·Òºó°ú °°Àº ±â¼ú Çõ½ÅÀ¸·Î ¾ÈÀü¼º°ú È¿´ÉÀÌ °³¼±µÇ¾î µ¿¹° À¯·¡ Á¦Ç°¿¡ ´ëÇÑ ¿ì·Á¸¦ ÇØ¼ÒÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ Æ®·ÒºóÀÇ Àç»ýÀÇ·á, »óó Ä¡À¯ µî »ý¸í°øÇÐ ¹× ÀǾàǰ¿¡ ´ëÇÑ Àû¿ëÀÌ È®´ëµÇ°í ÀÖ´Â °Íµµ ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ºÏ¹Ì´Â ÷´ÜÈ­µÈ ÀÇ·áÁ¦µµ¿Í À¯¸®ÇÑ »óȯÁ¤Ã¥À¸·Î ÇöÀç ÀÌ ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖÀ¸¸ç, À¯·´ÀÌ ±× µÚ¸¦ ÀÕ°í ÀÖÁö¸¸, Áß±¹°ú Àεµ¸¦ Áß½ÉÀ¸·Î ÇÑ ¾Æ½Ã¾Æ ½ÅÈï ½ÃÀåÀº Å« ¼ºÀå ÀáÀç·ÂÀ» °¡Áö°í ÀÖ½À´Ï´Ù. ±×·¯³ª ³ôÀº Á¦Á¶ºñ¿ë, ¾ö°ÝÇÑ ±ÔÁ¦, ´Ù¸¥ ÁöÇ÷Á¦¿ÍÀÇ °æÀï µîÀÇ ¹®Á¦´Â ½ÃÀå È®´ëÀÇ À§Çè¿ä¼Ò·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

¼­·Ð

  • Á¶»çÀÇ ¸ñÀû
  • Á¶»ç ¹üÀ§
  • Á¤ÀÇ

Á¶»ç ¹æ¹ý

  • Á¤º¸ Á¶´Þ
  • 2Â÷¿Í 1Â÷ µ¥ÀÌÅÍ ¹æ¹ý
  • ½ÃÀå ±Ô¸ð ¿¹Ãø
  • ½ÃÀåÀÇ ÀüÁ¦Á¶°Ç°ú Á¦ÇÑ

°³¿ä

  • ¼¼°è ½ÃÀå Àü¸Á
  • °ø±Þ°ú ¼ö¿ä µ¿Ç⠺м®
  • ºÎ¹®º° ±âȸ ºÐ¼®

½ÃÀå ¿ªÇаú Àü¸Á

  • ½ÃÀå °³¿ä
  • ½ÃÀå ±Ô¸ð
  • ½ÃÀå ¿ªÇÐ
    • ÃËÁø¿äÀΰú ±âȸ
    • ¾ïÁ¦¿äÀΰú °úÁ¦
  • PorterÀÇ »ê¾÷ ºÐ¼®

ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ®

  • ÁÖ¿ä ¼º°ø ¿äÀÎ
  • °æÀïÀÇ Á¤µµ
  • ÁÖ¿ä ÅõÀÚ ±âȸ
  • ½ÃÀå ¿¡ÄڽýºÅÛ
  • ½ÃÀåÀÇ ¸Å·Â Áö¼ö(2024³â)
  • PESTEL ºÐ¼®
  • °Å½Ã°æÁ¦ ÁöÇ¥
  • ¹ë·ùüÀÎ ºÐ¼®
  • °¡°Ý ºÐ¼®
  • »ç·Ê ¿¬±¸
  • °í°´ ±¸¸Å Çൿ ºÐ¼®

Æ®·Òºó ½ÃÀå ±Ô¸ð : Á¦Ç°º° & CAGR(2025-2032³â)

  • ½ÃÀå °³¿ä
  • ¼Ò Æ®·Òºó
  • Àΰ£ Æ®·Òºó
  • ÀçÁ¶ÇÕ Æ®·Òºó

Æ®·Òºó ½ÃÀå ±Ô¸ð : Á¦Çüº° & CAGR(2025-2032³â)

  • ½ÃÀå °³¿ä
  • ºÐ¸»»ó
  • ¼Ö·ç¼Ç Æû

Æ®·Òºó ½ÃÀå ±Ô¸ð : ÃÖÁ¾»ç¿ëÀÚº° & CAGR(2025-2032³â)

  • ½ÃÀå °³¿ä
  • º´¿ø
  • Áø´Ü ¼¾ÅÍ
  • ¿¬±¸±â°ü

Æ®·Òºó ½ÃÀå ±Ô¸ð & CAGR(2025-2032³â)

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • µ¶ÀÏ
    • ½ºÆäÀÎ
    • ÇÁ¶û½º
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • GCC ±¹°¡
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

°æÀï Á¤º¸

  • »óÀ§ 5»çÀÇ ºñ±³
  • ÁÖ¿ä ±â¾÷ÀÇ ½ÃÀå Æ÷Áö¼Å´×(2024³â)
  • ÁÖ¿ä ½ÃÀå ±â¾÷ÀÌ Ã¤ÅÃÇÑ Àü·«
  • ÃÖ±Ù ½ÃÀå µ¿Çâ
  • ±â¾÷ÀÇ ½ÃÀå Á¡À¯À² ºÐ¼®(2024³â)
  • ÁÖ¿ä ±â¾÷ÀÇ ±â¾÷ °³¿ä
    • ±â¾÷ÀÇ »ó¼¼
    • Á¦Ç° Æ÷Æ®Æú¸®¿À ºÐ¼®
    • ±â¾÷ÀÇ ºÎ¹®º° Á¡À¯À² ºÐ¼®
    • ¸ÅÃâÀÇ Àü³â´ëºñ ºñ±³(2022-2024³â)

ÁÖ¿ä ±â¾÷ °³¿ä

  • Pfizer Inc.
  • Johnson & Johnson Services Inc.
  • Baxter International Inc.
  • Shanghai RAAS Blood Products Co. Ltd.
  • GE Healthcare
  • Bayer AG
  • CSL Behring
  • Grifols
  • Hualan Biological Engineering
  • Haematologic Technologies Inc.
  • Octapharma AG
  • Omrix Biopharmaceuticals Ltd.
  • Japan Blood Products Organization
  • Mallinckrodt Pharmaceuticals
  • Mochida Pharmaceutical Co. Ltd.

°á·Ð°ú Á¦¾È

KSA 25.09.09

Global Thrombin Market size was valued at USD 628.4 million in 2023 and is poised to grow from USD 662.96 million in 2024 to USD 1017.44 million by 2032, growing at a CAGR of 5.5% during the forecast period (2025-2032).

The thrombin market is experiencing notable growth, driven by its critical role in hemostasis and blood coagulation, particularly in surgical and trauma settings. Increasing surgical procedures, including cardiovascular and orthopedic surgeries, alongside a growing aging population demanding enhanced medical care, are key growth factors. Innovations like recombinant thrombin have improved safety and efficacy, addressing concerns related to animal-derived products. Additionally, thrombin's expanding applications in biotechnology and pharmaceuticals, such as regenerative medicine and wound healing, contribute to market expansion. North America currently dominates this market due to its advanced healthcare system and favorable reimbursement policies, followed by Europe, while emerging markets in Asia, notably China and India, present significant growth potential. However, challenges such as high manufacturing costs, strict regulations, and competition from other hemostatic agents pose risks to market progression.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Thrombin market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Thrombin Market Segments Analysis

Global Thrombin Market is segmented by Product, Dosage Form, End-User and region. Based on Product, the market is segmented into Bovine Thrombin, Human Thrombin and Recombinant Thrombin. Based on Dosage Form, the market is segmented into Powder Form and Solution Form. Based on End-User, the market is segmented into Hospitals, Diagnostic Centers and Research Institutions. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Thrombin Market

The global thrombin market is driven by the rising number of surgical procedures, influenced by an aging population and the growing prevalence of non-communicable diseases such as cardiovascular conditions and cancer. With over 310 million surgeries conducted annually worldwide, the demand for thrombin-based products continues to soar, as thrombin is utilized in around 65% of cardiovascular surgeries and 55% of orthopedic procedures for local hemostasis. Additionally, the shift towards more minimally invasive surgical techniques necessitates effective hemostatic solutions like thrombin, which play a critical role in ensuring successful patient outcomes and enhancing overall surgical efficiency.

Restraints in the Global Thrombin Market

The global thrombin market faces significant constraints due to the high costs associated with thrombin production, particularly in the case of recombinant thrombin, which is a sophisticated biotechnological product. These elevated prices restrict its accessibility and application, particularly in healthcare facilities in developing regions where financial resources are limited. Consequently, many of these institutions may opt for more economical hemostatic alternatives, limiting the expansion and utilization of thrombin products in these markets. The high production costs thus pose a barrier to broader market penetration, hindering the integration of advanced hemostatic solutions in economically challenged healthcare settings.

Market Trends of the Global Thrombin Market

The Global Thrombin market is witnessing a notable shift towards the adoption of recombinant thrombin products, driven by their superior safety, purity, and consistency compared to traditional bovine-derived alternatives. This trend is fueled by the increasing emphasis on patient safety and the demand for effective hemostatic agents in surgical procedures. Additionally, the rise of minimally invasive surgical techniques necessitates reliable hemostasis, further propelling the utilization of advanced thrombin solutions. As healthcare providers seek to enhance procedural outcomes while minimizing complications, the preference for recombinant thrombin products is set to gain momentum, shaping the future landscape of the thrombin market.

Table of Contents

Introduction

  • Objectives of the Study
  • Scope of the Report
  • Definitions

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Methods
  • Market Size Estimation
  • Market Assumptions & Limitations

Executive Summary

  • Global Market Outlook
  • Supply & Demand Trend Analysis
  • Segmental Opportunity Analysis

Market Dynamics & Outlook

  • Market Overview
  • Market Size
  • Market Dynamics
    • Drivers & Opportunities
    • Restraints & Challenges
  • Porters Analysis
    • Competitive rivalry
    • Threat of substitute
    • Bargaining power of buyers
    • Threat of new entrants
    • Bargaining power of suppliers

Key Market Insights

  • Key Success Factors
  • Degree of Competition
  • Top Investment Pockets
  • Market Ecosystem
  • Market Attractiveness Index, 2024
  • PESTEL Analysis
  • Macro-Economic Indicators
  • Value Chain Analysis
  • Pricing Analysis
  • Case Studies
  • Customer Buying Behavior Analysis

Global Thrombin Market Size by Product & CAGR (2025-2032)

  • Market Overview
  • Bovine Thrombin
  • Human Thrombin
  • Recombinant Thrombin

Global Thrombin Market Size by Dosage Form & CAGR (2025-2032)

  • Market Overview
  • Powder Form
  • Solution Form

Global Thrombin Market Size by End-User & CAGR (2025-2032)

  • Market Overview
  • Hospitals
  • Diagnostic Centers
  • Research Institutions

Global Thrombin Market Size & CAGR (2025-2032)

  • North America (Product, Dosage Form, End-User)
    • US
    • Canada
  • Europe (Product, Dosage Form, End-User)
    • Germany
    • Spain
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific (Product, Dosage Form, End-User)
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America (Product, Dosage Form, End-User)
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (Product, Dosage Form, End-User)
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Competitive Intelligence

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2024
  • Strategies Adopted by Key Market Players
  • Recent Developments in the Market
  • Company Market Share Analysis, 2024
  • Company Profiles of All Key Players
    • Company Details
    • Product Portfolio Analysis
    • Company's Segmental Share Analysis
    • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

  • Pfizer Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Johnson & Johnson Services Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Baxter International Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Shanghai RAAS Blood Products Co. Ltd.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • GE Healthcare
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bayer AG
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • CSL Behring
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Grifols
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Hualan Biological Engineering
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Haematologic Technologies Inc.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Octapharma AG
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Omrix Biopharmaceuticals Ltd.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Japan Blood Products Organization
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Mallinckrodt Pharmaceuticals
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Mochida Pharmaceutical Co. Ltd.
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments

Conclusion & Recommendations

»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦